Click here to go to the previous page
Doping Abuse of Medicines in Sport: The Challenge to Industry and Regulators
Program Code:
390
Date:
Wednesday, June 27, 2012
Time:
3:30 PM to 5:00 PM
EST
CHAIR
:
Barbara has over 30 years experience in the pharmaceutical industry, primarily in clinical drug development. In Roche, she has been responsible for numerous regional and global regulatory submissions. She is currently responsible for quality risk management in safety science/pharmacovigilance
|
PRESENTER
(S):
WADA’s Science Director since Sept 2002, worked for IPSEN Pharma in research and business development. Prior to his work at IPSEN, was a principal investigator in research in pharmacology and toxicology in public organizations has a PhD degree Toxicology & a degree in biomedical engineering.
|
Steven Elliott, Amgen Inc., United States
Mark Luttmann, Glaxosmithkline, United States
Description
Ahead of the 2012 Olympics, this session will highlight the many and varied ways in which medicines are misused for performance enhancement and address opportunities for companies to work proactively with World Anti-Doping Agency (WADA) to mitigate the risk of abuse.
Learning Objectives:
Recognize the danger of doping abuse and how this can be addressed through collaboration with World Anti-Doping Agency (WADA)
Evaluate the approaches used by different companies in proactively addressing potential for doping abuse of their medicines.